Aiken T, Erbe A, Zebertavage L, Komjathy D, Feils A, Rodriguez M, et al. Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma. J Immunother Cancer. 2022;10: pubmed publisher

Taylor J, Bulek A, Gannon I, Robson M, Kokalaki E, Grothier T, et al. Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2. Front Immunol. 2023;14:1119350 pubmed publisher

Jaggupilli A, Ly S, Nguyen K, Anand V, Yuan B, El Dana F, et al. Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer. Br J Cancer. 2022;126:615-627 pubmed publisher

Raman S, Buongervino S, Lane M, Zhelev D, Zhu Z, Cui H, et al. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Rep Med. 2021;2:100344 pubmed publisher

Carlson P, Mohan M, Patel R, Birstler J, Nettenstrom L, Sheerar D, et al. Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice. J Immunol. 2021;207:720-734 pubmed publisher

Zobel M, Zamora A, Wu H, Sun J, Lascano D, Malvar J, et al. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice. J Immunother Cancer. 2020;8: pubmed publisher

Voeller J, Erbe A, Slowinski J, Rasmussen K, Carlson P, Hoefges A, et al. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. J Immunother Cancer. 2019;7:344 pubmed publisher

Barry W, Jackson J, Asuelime G, Wu H, Sun J, Wan Z, et al. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma. Clin Cancer Res. 2019;25:325-333 pubmed publisher